Serotonin transporter: Gene, genetic disorders, and pharmacogenetics

被引：319
作者：
Murphy, DL
Lerner, A
Rudnick, G
Lesch, KP
机构：
[1] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA
[2] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
[3] Univ Wurzburg, Dept Psychiat & Psychotherapy, D-97070 Wurzburg, Germany
来源：
MOLECULAR INTERVENTIONS | 2004年 / 4卷 / 02期
关键词：
D O I：
10.1124/mi.4.2.8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The highly evolutionarily conserved serotonin transporter (SERT) regulates the entire serotoninergic system and its receptors via modulation of extracellular fluid serotonin concentrations. Differences in SERT expression and function produced by three SERT genes and their variants show associations with multiple human disorders. Screens of DNA from patients with autism, ADHD, bipolar disorder, and Tourette's syndrome have detected signals in the chromosome 17q region where SERT is located. Parallel investigations of SERT knockout mice have uncovered multiple phenotypes that identify SERT as a candidate gene for additional human disorders ranging from irritable bowel syndrome to obesity. Replicated studies have demonstrated that the SERT 5'-flanking region polymorphism SS genotype is associated with poorer therapeutic responses and more frequent serious side effects during treatment with antidepressant SERT antagonists, namely, the serotonin reuptake inhibitors (SRIs).
引用
收藏
页码：109 / 123
页数：15
相关论文
共 162 条
  • [21] The serotonin transporter is a potential susceptibility factor for bipolar affective disorder
    Collier, DA
    Arranz, MJ
    Sham, P
    Battersby, S
    Vallada, H
    Gill, P
    Aitchison, KJ
    Sodhi, M
    Li, T
    Roberts, GW
    Smith, B
    Morton, J
    Murray, RM
    Smith, D
    Kirov, G
    [J]. NEUROREPORT, 1996, 7 (10) : 1675 - 1679
  • [22] Association of the serotonin transporter gene with serum cholesterol levels and heart disease
    Comings, DE
    MacMurray, JP
    Gonzalez, N
    Ferry, L
    Peters, WR
    [J]. MOLECULAR GENETICS AND METABOLISM, 1999, 67 (03) : 248 - 253
  • [23] Valvular heart disease associated with fenfluramine-phentermine
    Connolly, HM
    Crary, JL
    McGoon, MD
    Hensrud, DD
    Edwards, BS
    Edwards, WD
    Schaff, HV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) : 581 - 588
  • [24] CONROY J, 2004, MOL PSYCHIAT 0106
  • [25] Cook EH, 1997, MOL PSYCHIATR, V2, P247
  • [26] AUTORADIOGRAPHY OF ANTIDEPRESSANT BINDING-SITES IN THE HUMAN-BRAIN - LOCALIZATION USING [H-3]IMIPRAMINE AND [H-3] PAROXETINE
    CORTES, R
    SORIANO, E
    PAZOS, A
    PROBST, A
    PALACIOS, JM
    [J]. NEUROSCIENCE, 1988, 27 (02) : 473 - 496
  • [27] 5-hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction
    Coto, E
    Reguero, JR
    Alvarez, V
    Morales, B
    Batalla, A
    González, P
    Martín, M
    García-Castro, M
    Iglesias-Cubero, G
    Cortina, A
    [J]. CLINICAL SCIENCE, 2003, 104 (03) : 241 - 245
  • [28] DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
  • [29] A novel allelic variant of the human serotonin transporter gene regulatory polymorphism
    Delbrück, SJW
    Wendel, B
    Grunewald, I
    Sander, T
    Morris-Rosendahl, D
    Crocq, MA
    Berrettini, WH
    Hoehe, MR
    [J]. CYTOGENETICS AND CELL GENETICS, 1997, 79 (3-4): : 214 - 220
  • [30] Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response
    Di Bella D.
    Erzegovesi S.
    Cavallini M.C.
    Bellodi L.
    [J]. The Pharmacogenomics Journal, 2002, 2 (3) : 176 - 181
12345678910